{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:46:24Z","timestamp":1788893184205,"version":"build-2803163510"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2024,4,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Traditionally, cephalothin susceptibility results were used to predict the susceptibility of additional cephalosporins; however, in 2013\u20132014, the Clinical and Laboratory Standards Institute (CLSI) revisited this practice and determined that cefazolin is a more accurate proxy than cephalothin for uncomplicated urinary tract infections (uUTIs). Therefore, a cefazolin surrogacy breakpoint was established to predict the susceptibility of seven oral cephalosporins for\n              <jats:italic>Escherichia coli<\/jats:italic>\n              ,\n              <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n              , and\n              <jats:italic>Proteus mirabilis<\/jats:italic>\n              in the context of uUTIs. Clinical microbiology laboratories face several operational challenges when implementing the cefazolin surrogacy breakpoint, which may lead to confusion for the best path forward. Here, we review the historical context and data behind the surrogacy breakpoints, review PK\/PD profiles for oral cephalosporins, discuss challenges in deploying the breakpoint, and highlight the limited clinical outcome data in this space.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/jcm.00788-21","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T16:35:35Z","timestamp":1709915735000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Cefazolin as a predictor of urinary cephalosporin activity in indicated Enterobacterales"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-7829","authenticated-orcid":false,"given":"Alexandra L.","family":"Bryson","sequence":"first","affiliation":[{"name":"Department of Pathology, Virginia Commonwealth University Health System, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Bhalodi","sequence":"additional","affiliation":[{"name":"Scientific and Medical Affairs Consulting, Newton, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael M.","family":"Liesman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Mathers","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health, Charlottesville, Virginia, USA"},{"name":"Clinical Microbiology Laboratory, Department of Pathology, University of Virginia Health, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","first-page":"20525","article-title":"Rules and regulations","volume":"37","author":"Food and Drug Administriation","year":"1972","unstructured":"Food and Drug Administriation, Department of Health, Education, and Welfare. 1972. Rules and regulations. Fed Regist 37:20525\u201320529.","journal-title":"Fed Regist"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.03.022"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.08.024"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/am.19.4.589-593.1970"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/70.6.909"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00968-07"},{"key":"e_1_3_1_8_2","unstructured":"EUCAST. Antimicrobial wild type distributions of microorganisms: E. coli. Available from: https:\/\/mic.eucast.org\/search\/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=-1&search%5Bspecies%5D=261&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50. Accessed 21 July 2023"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2047"},{"key":"e_1_3_1_11_2","volume-title":"CLSI M100 ED33 performance standards for antimicrobial susceptiblity testing","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. CLSI M100 ED33 performance standards for antimicrobial susceptiblity testing. 33rd ed","edition":"33"},{"key":"e_1_3_1_12_2","first-page":"1","volume-title":"CLSI rational document MR08","author":"Humphries R.M.","year":"2020","unstructured":"Humphries, R.M., A.N. Schutez, and C. Mintz, Cefazolin breakpoints for Enterobacterales (uncomplicated urinary tract infections). CLSI rational document MR08, 2020: p. 1-12."},{"key":"e_1_3_1_13_2","unstructured":"CLSI. 2013. Summary minutes subcommittee on antimicrobial susceptiblity testing June 2013:12\u201315."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115299"},{"key":"e_1_3_1_15_2","unstructured":"DURICEF (cefadroxil monohydrate USP). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/50512s44lbl.pdf. 5 March 2002. Accessed 5 March 2002"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115053"},{"key":"e_1_3_1_17_2","unstructured":"EUCAST. 2023. The European committee on antimicrobial susceptibility testing. breakpoint tables for interpretation of mics and zone diameters. version 13.1. Available from: http:\/\/www.eucast.org"},{"key":"e_1_3_1_18_2","unstructured":"FDA. 2021. U.S. Food and Drug Administration - recognized antimicrobial susceptilbity test interpretive criteria. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/cefazolin-injection-products"},{"key":"e_1_3_1_19_2","unstructured":"EUCAST. 2020. Why do EUCAST have no systemic breakpoints for Enterobacterales with oral cephalosporins? Oral cephalosporins and Enterobacterales. version 2. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance_documents\/Oral_ceph_breakpoints_v2_20200710.pdf"},{"key":"e_1_3_1_20_2","unstructured":"FDA. 2022. Rationale for FDA\u2019s position on the use of cefazolin breakpoints as a surrogate for determining breakpoints for oral cephalosporins for the treatment of uncomplicated urinary tract infections. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/rationale-fdas-position-use-cefazolin-breakpoints-surrogate-determining-breakpoints-oral"},{"key":"e_1_3_1_21_2","unstructured":"Hinder JA Schuetz AN. 2021. CLSI subcommittee on antimicrobial susceptiblity testing: CLSI AST NEW update 6:7\u201311."},{"key":"e_1_3_1_22_2","unstructured":"EUCAST. 2019. New definitions of S I and R from 2019. Available from: https:\/\/www.eucast.org\/newsiandr"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197203010-00002"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.229"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106085"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.900551"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.3.457"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.2.331"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.1.1"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.2.320"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.1204"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.12.2.157"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/25.5.831"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.144"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.4.504"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/16.5.646"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.152"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1082"},{"key":"e_1_3_1_39_2","unstructured":"Omnicef (cefdinir). 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1999\/50739S2LBL.PDF"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.2.232"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.suppl_e.21"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1991.tb03686.x"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03203.x"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000310"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.3.485"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac025"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.8.949"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.80"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2612"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.897-900.2003"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(99)00118-1"},{"key":"e_1_3_1_53_2","first-page":"135","article-title":"Treatment of urinary tract infection with cephalexin","volume":"17","author":"Kostas CI","year":"1983","unstructured":"Kostas CI, Mobley DF, Rous SN, Schneider RE, Burt RA. 1983. Treatment of urinary tract infection with cephalexin. J Fam Pract 17:135,","journal-title":"J Fam Pract"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1177\/00099228221112055"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2023.1979"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.12.1896"},{"key":"e_1_3_1_57_2","unstructured":"FDA. 2023. Devices@FDA 510(k) number: K222073 VITEK 2 AST-gram negative cefazolin (<=1 - >=32 ug\/mL). Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/devicesatfda\/index.cfm?db=pmn&id=K222073. Retrieved 16 Jan 2024."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00788-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00788-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T23:14:23Z","timestamp":1715814863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00788-21"}},"subtitle":[],"editor":[{"given":"Romney M.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,10]]}},"alternative-id":["10.1128\/jcm.00788-21"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00788-21","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"2024-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00788-21"}}